Weei-Chin Lin, M.D., Ph.D.
Picture
Weei-Chin Lin, M.D., Ph.D.
Professor of Medicine
Positions
- Professor of Medicine
-
Medicine-Hematology & Oncology
草榴社区入口
Houston, TX US
- Professor
-
Department of Molecular and Cellular Biology
草榴社区入口
Houston, Texas United States
- Dan L Duncan Professorship
-
Dan L Duncan Comprehensive Cancer Center
草榴社区入口
Houston, Texas United States
- Program Director
-
BCM Oncology Scholars Training Program (T32)
草榴社区入口
Houston, Texas United States
- Co-Director
-
Program in Integrative Molecular and Biomedical Sciences
草榴社区入口
- Co-Director
-
Cancer & Cell Biology Graduate Program
草榴社区入口
- Faculty
-
Development, Disease Models & Therapeutics Graduate Program
草榴社区入口
- Faculty
-
Program in Translational Biology and Molecular Medicine
草榴社区入口
Addresses
- Alkek Building for Biomedical Research (Office)
-
Room: ABBR-R410
Houston, TX 77030
United States
Education
- PhD from Johns Hopkins University School Of Medicine
- 05/1993 - Baltimore, Maryland United States
- MD from National Taiwan University
- 06/1986 - Taipei, Taiwan Taiwan
- Post-Doctoral Fellowship at Johns Hopkins University School of Medicine
- 06/1994 - Baltimore, Maryland United States
- Residency at Duke University Medical Center
- 06/1996 - Durham, North Carolina United States
- Clinical Fellowship at Duke University Medical Center
- 06/1999 - Durham, North Carolina United States
Certifications
- Texas Medical Board
- Diplomate, American Board of Internal Medicine
- Subspecialty in Medical Oncology, ABIM
- Subspecialty in Hematology, ABIM
Honors & Awards
- Dan Duncan Professorship of Oncology
- 草榴社区入口 (01/2010)
- The Leukemia & Lymphoma Society Scholar
- 07/2006 - 06/2011
- General Motors Cancer Research Scholar
- 01/2002 - 01/2005
- Howard Hughes Medical Institute Junior Faculty Development Award
- 06/2001 - 06/2004
- Damon Runyon-Walter Winchell Physician Scientist Award
- Duke University (04/1999 - 05/2001)
- The Martin and Carol Macht Research Prize
- Johns Hopkins University (05/1993)
Professional Interests
- Cell cycle regulation
- Development of cancer therapeutics
- Clinical hematology
Professional Statement
I am a physician scientist with solid training in both clinical medicine and basic research. My lab is working on fundamental cell cycle/cell death regulation, and protein modifications, particularly focused on the pRb/E2F and p53 pathways in the oncogenic activation. We have identified several important pathways that are deregulated in cancer. My goal is to develop novel cancer therapy based on our own original discoveries.Websites
Selected Publications
- "." ;
- Fang-Tsyr Lin, Kang Liu, Lidija A Wilhelms Garan, Helena Folly-Kossi, Yongcheng Song, Shwu-Jiuan Lin, Weei-Chin Lin "." Proc Natl Acad Sci U S A. 2023 Oct 25; Pubmed PMID:
- Folly-Kossi H, Graves JD, Wilhelms Garan LA, Lin FT, Lin WC. "." Cancer Res Commun.. 2023 Oct 16;3(10):2096-112. Pubmed PMID:
- Lin WC, Lin FT "." Proc Natl Acad Sci U S A.. 2022 Dec 5;119(50):e2217953119.
- Garan LA, Xiao Y, Lin WC "." Proc Natl Acad Sci U S A.. 2022 Oct 17;119(43):e2209211119. Pubmed PMID:
- Ho SR, Lee YC, Ittmann MM, Lin FT, Chan KS, Lin WC "." Cancer Lett.. 2021 Aug 13;520(2021):344-360. Pubmed PMID:
- Liu K, Graves JD, Lin FT, Lin WC "." J Biol Chem. 2021 Feb 5;https://doi.org/10.1016/j.jbc.2021.100382 Pubmed PMID:
- Xiao Y, Lin FT, Lin WC "." Proc Natl Acad Sci U S A. 2021 Jan 19;118(3):1-12. Pubmed PMID:
- Graves JD, Lee YJ, Liu K, Li G, Lin FT, Lin WC "." Proc Natl Acad Sci U S A. 2020 Jun 30;117(26):11958-14969. Pubmed PMID:
- Liu K, Graves JD, Lee YJ, Lin FT, Lin WC "." Mol Cell Biol. 2020 Mar 30;40(8):1-19. Pubmed PMID:
- Lee YJ, Ho SR, Graves JD, Xiao Y, Huang S, Lin WC "." Breast Cancer Res. 2019 Dec 4;21(1):1-22. Pubmed PMID:
- Ho SR, Lin WC "." J Biol Chem. 2018 Oct 19;293(42):16307-16323. Pubmed PMID:
- Liu K, Lin FT, Graves JD, Lee YJ, and Lin WC. "." Proc Natl Acad Sci U S A. 2017 Apr 24;doi: 10.1073/pnas.1619832114(PNAS Early Edition):1-10. Pubmed PMID:
- Mahanic CS, Budhavarapu V, Graves JD, Li G, Lin WC. "." J Biol Chem. 2015 Oct 30;290(44):26508-22. Pubmed PMID:
- Ho SR, Lee YJ, Lin WC. "." J Biol Chem. 2015 Sep 18;290(38):23026-38. Pubmed PMID:
- Chowdhury P, Lin GE, Liu K, Song Y, Lin FT, Lin WC "." Nat Commun.. 2014 Nov 17;(5):5476. Pubmed PMID:
- Ho SR, Mahanic CS, Lee YJ, Lin WC "." Proc Natl Acad Sci U S A.. 2014 Jul 1;111(26):E2646-55. Pubmed PMID:
- Xiao Y, Lin VY, Ke S, Lin GE, Lin FT, Lin WC "." Mol Cell Biol.. 2014 May 12;34(14):2635-49. Pubmed PMID:
- Liu K, Graves JD, Scott JD, Li R, Lin WC "." Mol Cell Biol.. 2013 Dec;33(23):4685-700. Pubmed PMID:
- Budhavarapu VN, White ED, Mahanic CS, Chen L, Lin FT, Lin WC "." Cell Cycle. 2012 May 15;11(10):2030-8. Pubmed PMID:
- Liu K, Ling S, Lin WC "." Mol. Cell. Biol.. 2011 Nov;31(22):4464-81. Pubmed PMID:
- Ling S, Lin WC "." J. Biol. Chem.. 2011 Apr 29;286(17):14972-82. Pubmed PMID:
- Wang B, Liu K, Lin HY, Bellam N, Ling S, Lin WC "." Mol. Cell. Biol.. 2010 Mar;30(6):1508-27. Pubmed PMID:
- Paik JC, Wang B, Liu K, Lue JK, Lin WC "." J. Biol. Chem.. 2010 Feb 26;285(9):6348-63. Pubmed PMID:
- Liu K, Bellam N, Lin HY, Wang B, Stockard CR, Grizzle WE, Lin WC "." Mol. Cell. Biol.. 2009 May;29(10):2673-93. Pubmed PMID:
- Yang SZ, Lin FT, Lin WC "." EMBO Rep.. 2008 Sep;9(9):907-15. Pubmed PMID:
- Liu K, Paik JC, Wang B, Lin FT, Lin WC "." EMBO J.. 2006 Oct 18;25(20):4795-807. Pubmed PMID:
- Luo Y, Lin FT, Lin WC "." Mol. Cell. Biol.. 2004 Jul;24(14):6430-44. Pubmed PMID:
- Liu K, Luo Y, Lin FT, Lin WC "." Genes Dev.. 2004 Mar 15;18(6):673-86. Pubmed PMID:
- Liu K, Lin FT, Ruppert JM, Lin WC "." Mol. Cell. Biol.. 2003 May;23(9):3287-304. Pubmed PMID:
- Lin WC, Lin FT, Nevins JR "." Genes Dev. 2001 Jul 15;15(14):1833-44. Pubmed PMID:
- Lin WC, Desiderio S "." Immunol Today .. 1995 Jun 16;16(6):279-89. Pubmed PMID:
- Lin WC, Desiderio S "." Proc Natl Acad Sci U S A. 1994 Mar 29;91(7):2733-7. Pubmed PMID:
- Lin WC, Desiderio S "." Science. 1993 May 14;260(5110):953-9. Pubmed PMID:
Funding
- Novel therapeutics for targeting checkpoint dysfunction in cancer - #R01 CA203824
- $1,912,345.00 (12/15/2016 - 01/31/2027) Grant funding from NIH/NCI
- The goal of this project is to investigate cell cycle checkpoint defects for cancer therapy.
- 14-3-3tau drives estrogen receptor loss and breast cancer progression - #R01 CA269971
- $1,830,000.00 (04/17/2023 - 03/31/2028) Grant funding from NIH/NCI
- The goal of this project is to investigate a role of 14-3-3tau for estrogen receptor loss in ER(+) breast cancer progression.
- Synthetic Lethal Combination Targeting TopBP1 and Arachidonic Acid Pathway in Breast Cancer - #BC230488
- $1,600,000.00 (03/01/2024 - 02/28/2027) Grant funding from Department of Defense
- This project will investigate a new approach to target the arachidonic acid metabolism in breast cancer.
- Novel synthetic lethal therapies for triple-negative breast cancer - #BC210863
- $800,000.00 (05/15/2022 - 05/14/2025) Grant funding from Department of Defense
- The goal of this project is to develop novel targeted therapies against N-linked glycosylation in triple-negative breast cancer.
- New therapeutics targeting MYC and immune escape in lung cancer - #LC210369
- $560,000.00 (08/01/2022 - 07/31/2025) Grant funding from Department of Defense
- This project aims to develop novel MYC-targeting therapeutics for enhancing the response to immune checkpoint inhibitors in lung cancer.
Intellectual Property
- Method Patent #US 9,636,323 (Approved)
- The present invention provides a method of treating cancer that overexpresses TopBP1 by administering to a patient suffering from the cancer with an effective amount of a small molecule inhibitor that binds the BRCT7/8 domain of TopBP1.
- Co Inventors: Weei-Chin Lin, Pinki Chowdhury, Gregory E. Lin, Kang Liu, Yongcheng Song, Fang-Tsyr Lin
- Product Patent #PCT/US24/48843 (Pending)
- Small molecule inhibitors of TopBP1-BRCT7/8 and uses thereof
- Co Inventors: Weei-Chin Lin, Fang-Tsyr Lin
to edit your profile
